Jackisch C, et al. - In this final analysis of a randomized clinical trial of 596 patients, researchers examined the long-term efficacy and safety of subcutaneous trastuzumab vs intravenous trastuzumab for patients with ERBB2 (HER2)–positive early breast cancer. They adinistered 8 cycles of chemotherapy (4 cycles of docetaxel, 75 mg/m², followed by 4 cycles of fluorouracil, 500 mg/m², epirubicin, 75 mg/m², and cyclophosphamide, 500 mg/m²) with either fixed-dose subcutaneous trastuzumab, 600 mg, or intravenous trastuzumab (loading dose, 8 mg/kg; maintenance dose, 6 mg/kg) every 3 weeks to the eligible patients in the neoadjuvant setting. Both subcutaneous and intravenous trastuzumab groups had 6-year event-free survival rates of 65% and 6-year overall survival rates of 84%. with a comparable safety profile. Subcutaneous trastuzumab treatment was thus supported as suitable for patients with ERBB2-positive early breast cancer.